Pulmonary Hypertension
Conditions
Keywords
Vascular Diseases, Lung Diseases, Respiratory Tract Diseases
Brief summary
The aim of this study is to investigate the underlying inflammatory profile in patients with chronic lung disease and determine the association pulmonary hypertension.
Detailed description
Chronic lung diseases (CLD), such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are often complicated by the presence of pulmonary hypertension (PH), where even a mild elevation of blood pressure in the pulmonary arteries is associated with an even poorer prognosis. In this study, we will investigate whether similarities exist in the inflammatory profile that could potentially underlie all forms of pulmonary hypertension. Inflammatory data will be generated using flow cytometry, expression profiling and histological analysis and compared to the associated clinical data.
Interventions
OTHERTissue sampling
Blood collection via venipuncture into citrate- or ethylenediaminetetraacetic (EDTA)-containing vacutainer tubes and into serum tubes. Explant lung tissue obtained from patients that underwent lung transplantation. Non-transplanted donor lungs that had been harvested for transplantation, but not implanted because of size-reduction serve as controls.
Sponsors
Medical University of Graz
Medical University of Vienna
Ludwig Boltzmann Institute for Lung Vascular Research
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients undergoing lung transplant with COPD or IPF, with associated PH * Signed informed consent
Exclusion criteria
* patients without written informed consent * Signs of any infection such as pneumonia, pulmonary tuberculosis or infections with pleural effusions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Analysis of inflammatory cell profile | within 36 months | The number of leukocytes (CD45+ cells) and derivatives (percentage lymphocytes, monocytes and neutrophils) will be measured by flow cytometry in explanted lung tissue and blood of patients with CLD-PH and controls. Values will be reported as %CD45+ and %total cells. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Degree of pulmonary vascular disease | within 36 months | Pulmonary vascular disease will be assessed by associated clinical data (mPAP (mmHg), PVR (WU)) 1. CLD without PH (mPAP \<21 mmHg, or mPAP 21-24 mmHg with pulmonary vascular resistance (PVR) \<3 Wood Units (WU)). 2. CLD with PH (mPAP 21-24 mmHg with PVR ≥3 WU, or mPAP 25-34 mmHg) (CLD-PH). 3. CLD with severe PH (mPAP ≥35 mmHg, or mPAP ≥25 mmHg with low cardiac index (\<2.0 L·min-1·m-2)) (CLD-severe PH). |
Countries
Austria
Contacts
Primary ContactLeigh Marsh
Outcome results
None listed